Konrad Werhahn from UCB discusses how disease-modifying solutions may introduce a new era in treatment for epilepsies
Alex Fong and Olivia Houselander from Owen Mumford Pharmaceutical Services consider the action needed to make drug discovery processes more sustainable
Rajul Jain from ProPharma considers how AI can be used in patient support, especially considering how it can be used to streamline operations and supplement human expertise
Betsy Goodfellow from Pharmafocus considers the details of the infected blood scandal, from its beginning to the outcome of the recent inquiry
Page 4 –CHMP grants positive opinion to AbbVie’s Tepkinly for follicular lymphoma treatment
Page 6 – Takeda announces phase 3 results from trial of CIPD treatment
Page 8 – Merck’s Capvaxive approved by FDA for prevention of pneumococcal disease
Page 10 – Evotec provides update in Bristol Myers Squibb neuroscience collaboration
Page 12 – EyeBio to be acquired by Merck for an upfront $1.3bn
Executive Director
– PMGroup Worldwide Ltd
Karl Equi
Group Managing Editor
Iona Everson
Editorial Assistants
Betsy Goodfellow
betsy@pharmafile.com
Sales Manager
Eliot Haynes
Design & Layout
Peter May
Pharmafocus is published by:
Samedan Ltd
Suite E, 11 Bell Yard Mews,
175 Bermondsey Street,
London, SE1 3TN
Tel: +44 (0)20 7724 3456
Fax: +44 (0)20 7403 7747
Subscriptions & Data Management
Curwood CMS Tel: 01580 883840
ISSN: 1465-5403
Pharmafocus is sent free of charge to selected permanent employees of ethical and OTC pharmaceutical and biotech companies. Employees are specifiers from middle and senior management with responsibility for making buying decisions. Selection is at the discretion of the Publisher. Copies are also available on a subscription basis at an annual fee of £115 (UK), £145 (Europe) and £185 (RoW).
All subscriptions payable to Samedan. Back copies can be purchased for £15.00 each. Pharmafocus is published by Samedan Ltd. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form without permission, unless for the purposes of reference and comment.
©2024 Samedan Ltd, Pharmaceutical Publishers
The opinions and views expressed by contributors to this publication are not necessarily those of the Editor or the Publisher and, while every care has been taken in the preparation of the newspaper, the Editor and the Publisher are not responsible for such opinions and views, or for any inaccuracies in the articles. The Publisher is not responsible for any images supplied by contributors. While every care is taken with artwork supplied, the Publisher cannot be held responsible for any loss or damage incurred. The entire content of this publication is protected by copyright. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, by any means – electronic, mechanical, photocopying or otherwise – without the prior permission of the Publisher.